

ASX Announcement

27 November 2023

Closure of Share Sale Facility for Unmarketable Parcels

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce the completion of its unmarketable parcel share sale facility.

The facility was announced to ASX on 9 October 2023, and provided an opportunity for shareholders holding fully paid ordinary shares in the company valued at less than \$500 (an 'unmarketable parcel') to sell their holdings without incurring brokerage or other transaction costs. Based on the price of shares at the close of trading on 6 October 2023, a holding of less than 7,143 shares constituted an unmarketable parcel.

The facility closed as planned on 24 November 2023, having provided a period of at least six weeks for shareholders who wished to retain their shares to opt out.

Following closure of the facility, a total of 2,238,910 shares, held by 632 shareholders who did not elect to retain their holdings will now be sold. Antisense has engaged Morgans Corporate Limited to assist with disposal of the shares. The company has received inbound interest from institutional investors and will seek to sell the shares directly to those investors where possible.

The proceeds from the sale will be dealt with in accordance with the Company's constitution, and will be remitted to participating shareholders as soon as practicable following settlement of all shares sold through the facility.

The average sale price will be determined once all of the shares under the program are sold. Each shareholder will receive their proportionate share of the sale proceeds for all shares sold through the facility. If some or all of the shares are sold off-market, the sale price for those shares will be the price that the ANP directors have been able to negotiate with the acquirer(s). The process is anticipated to be completed, with payment made to the relevant shareholders, by the end of December 2023.

~ ENDS ~

This announcement has been authorised for release by the Board.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact info@antisense.com.au